Chronic Stress and Cortisol Elevation
Sustained psychological stress keeps circulating cortisol chronically elevated.
- +40–60%: Cortisol vs baseline (under chronic stress)
- ~90 min: Cortisol half-life (plasma clearance)
- ~8 AM: Circadian peak (normal diurnal rhythm)
- High: Cardiometabolic risk (with prolonged exposure)
What drives chronic elevation
Ongoing stressors keep the HPA axis switched on.
Chronic cortisol elevation disrupts sleep, mood and metabolism.
Cortisol as the stress hormone
Cortisol mobilizes glucose and suppresses non-essential functions.
Acute versus chronic stress
Acute cortisol spikes resolve; chronic elevation does not.
HPA-Axis Overactivity
Hypothalamus, pituitary and adrenal glands stay hyperactive together.
- Elevated: CRH release (hypothalamic output)
- Frequent: ACTH pulses (pituitary signaling)
- High: Adrenal cortisol output (sustained secretion)
- Impaired: Feedback inhibition (blunted negative feedback)
The three-node cascade
CRH triggers ACTH, which triggers adrenal cortisol release.
Feedback loop breakdown
Chronic activation blunts the normal cortisol feedback brake.
Impaired feedback lets cortisol stay elevated for weeks.
Downstream consequences
Overactive signaling strains sleep, immunity and mood regulation.
Ashwagandha Supplementation Begins
Withania somnifera extract starts modulating stress-signaling pathways.
- Withanolides: Active compounds (steroidal lactones)
- 300–600 mg: Typical trial dose (root extract per day)
- ~2 wks: Onset of effect (earliest measurable change)
- HPA axis: Mechanism target (proposed GABAergic action)
Proposed mechanism of action
Withanolides may mimic GABA and calm CRH signaling.
Dosing and timeline
Effects build gradually over several weeks of use.
Most trials use 300–600 mg standardized extract daily.
Early physiological response
Subjective stress scores often improve before cortisol shifts.
Cortisol Reduction
HPA-axis activity moderates as cortisol levels steadily decline.
- ~20–30%: Cortisol reduction (8 wks) (reported in RCTs)
- Multiple: Serum cortisol trials (randomized controlled)
- Improved: Perceived stress scale (self-reported outcomes)
- 6–12 wks: Trial duration range (typical study length)
Cortisol decline over time
Reduction tracks duration and consistency of supplementation.
Convergent trial findings
Several RCTs report significant serum cortisol reductions.
A 2019 meta-analysis found consistent cortisol-lowering effects.
Individual variability
Response magnitude varies with baseline stress and dose.
Evidence Strength Assessment
Trial evidence for cortisol-lowering is moderate, not definitive.
- Moderate: Evidence grade (per systematic reviews)
- ~10–12: RCTs reviewed (small-to-medium samples)
- 50–70: Typical sample size (participants per trial)
- Limited: Long-term safety data (beyond 3 months)
Why evidence is "moderate"
Trials are small, short, and vary in quality.
Larger, longer, standardized trials are still needed.
Risk-of-bias considerations
Some trials have funding or blinding limitations.
Clinical takeaway
Promising signal, but not yet definitive proof.